The Gastrointestinal (GI) Cancer group strives to:
- provide state-of-the-art treatments and therapies for those with colon, esophageal, stomach, pancreatic, and bile duct cancer as well as other more rare GI cancers
- serve as an educational resource for patients and the community about the disease
- provide an environment that stimulates excellence in cancer research.
Researchers focus on the development and evaluation of novel treatments for GI tract cancers. Many investigators are actively involved in studies with new compounds such as monoclonal antibodies, vaccines, and new chemotherapeutic agents. In addition, there is increasing evidence that some GI cancers may be hereditary, and the GI group has active clinical care and research programs in genetics and molecular markers of disease. For example, our institution sponsors the Hereditary Colorectal Tumor Registry initiative, a national database of patients whose cancers show a familial connection that places them at higher risk for developing cancer. This research registry captures high-risk subjects and collects information regarding their genetic makeup in an effort to diagnose, treat, and improve mortality in this group.
A multidisciplinary approach to the diagnosis and treatment of GI cancers is necessary to address the complexity of the disease. An experienced and dedicated team of gastroenterologists, medical oncologists, surgical oncologists, GI surgeons, radiation oncologists, pathologists, behavioral psychologists, dietitians, and oncology nurses provide patient care. UPCI and UPMC CancerCenter are very active in a number of clinical trials. In addition, The Gastrointestinal Cancer Prevention and Treatment Center concentrates on cancer prevention and optimizes the early diagnosis and treatment of cancers of the GI tract.
For more information on GI cancers and treatment options, visit the UPMC CancerCenter Colorectal & GI Cancers site or the Metastatic Colorectal Cancer Specialty Care site. Or, click here to find a clinical trial.